134665-72-8

Basic information

• Product Name: 2'-cyano-2'-deoxyarabinofuranosylcytosine
• Synonyms: 2'-cyano-2'-deoxyarabinofuranosylcytosine;CNDAC HCl salt;2'-Cyano-2'-deoxyarabinofuranosylcytosine hydrochloride;CNDAC hydrochloride;(2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-carbonitrile hydrochloride;CNDAC HCl
• CAS NO: 134665-72-8
• Molecular Formula: C₁₀H₁₂N₄O₄*ClH
• Molecular Weight: 288.68762
• Mol File: 134665-72-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 596.9°Cat760mmHg
• Flash Point: 314.8°C
• Appearance: /
• Density: g/cm³
• CAS DataBase Reference: 2'-cyano-2'-deoxyarabinofuranosylcytosine(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-cyano-2'-deoxyarabinofuranosylcytosine(134665-72-8)
• EPA Substance Registry System: 2'-cyano-2'-deoxyarabinofuranosylcytosine(134665-72-8)

Safety Data

• Hazardous Substances Data: 134665-72-8(Hazardous Substances Data)

Usage

General Description

2'-cyano-2'-deoxyarabinofuranosylcytosine, also known as CNDAC, is a synthetic nucleoside analog that shows promising anti-cancer activity. It has been studied for its potential as a therapeutic agent in the treatment of various types of cancer, including leukemia, lymphoma, and solid tumors. CNDAC acts by inhibiting DNA replication and inducing apoptosis in cancer cells. It has shown low toxicity to normal cells and has demonstrated synergistic effects when combined with other anti-cancer drugs, making it a potential candidate for combination therapy. Research on CNDAC is ongoing, with the goal of developing it into a safe and effective treatment for cancer.

Upstream product

• 135598-72-0 N⁴-acetyl-1-(2-C-cyano-2-deoxy-β-D-arabinofuranosyl)cytosine 
• 135598-71-9 N⁴-acetyl-1-<2-C-cyano-2-deoxy-3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-arabinofuranosyl>cytosine 

Downstream Products

• 135598-68-4 1-(2-cyano-2-deoxy-beta-D-arabinofuranosyl)cytosine 
• 71-30-7 Cytosine 

Relevant articles and documents

NOVEL STABLE CRYSTAL OF 1-(2'-CYANO-2'-DEOXY-BETA-D-ARABINOFURANOSYL)CYTOSINE MONOHYDROCHLORIDE

Disclosed is a stable crystal of 1-(2′-cyano-2′-deoxy-β-D-arabinofuranosyl)cytosine monohydrochloride. There is provided a crystal of 1-(2′-cyano-2′-deoxy-β-D-arabinofuranosyl)cytosine monohydrochloride having characteristic peaks at 13.7°, 15.7°, 16.0°, 18.6°, 20.3°, and 22.7° as diffraction angles (2θ±0.1°) measured by powder X-ray diffraction, and having a melting point of 192° C. to 197° C.

INTERMEDIATE AND PROCESSES INVOLVED IN THE PREPARATION OF 2 ' -CYANO-2 ' -DE0XY-N4-PALMIT0YL-1-BETA-ARABIN0FURAN0SYLCYTOSINE

The present invention relates to a process for preparing a compound of formula (682-6'), said process comprising the steps of: formula (682-4), (682-5), (682-6'): (i) converting a compound of formula (682-4) into a compound of formula (682-5); and (ii) converting said compound of formula (682-5) into a compound of formula (682- 6'). Further aspects of the invention relate to the use of the above process in the preparation of 2'-cyano-2'-deoxy-N4-palmitoyl-l-β-D-arabinofuranosylcytosine, a pyrimidine nucleoside which is therapeutically useful in the treatment and/or prevention of cancer.